Dapsone and body mass index in subjects with multibacillary leprosy.
BACKGROUND
The physiological changes in obese subjects can modify the pharmacokinetic profiles of drugs influencing the therapeutic efficacy.


METHODS
In this study, the authors compare plasma dapsone trough levels of multibacillary leprosy subjects stratified by body mass index (BMI) to evaluate if obesity plays a significant role on drug levels. The relationship between drug levels and BMI was also determined. Dapsone was measured by high-performance liquid chromatography and BMI based on World Health Organization criteria.


RESULTS
At steady state, the median plasma dapsone trough level was significantly lower in obesity class 2 group, when compared with other groups, but they were similar between normal weight and preobesity groups. A weak association between drug levels and BMI was observed.


CONCLUSIONS
Obesity promotes a significant reduction in plasma dapsone trough levels of subjects with multibacillary leprosy with a weak association between drug levels and BMI.
Health Science Institute, Universidade Federal do Pará, Belem, Brazil.
Fernanda M L
FM
Moura
Rosa M
RM
Dias
Eliete C
EC
Araujo
Laélia M B F
LM
Brasil
Michelle V D
MV
Ferreira
Jose L F
JL
Vieira
D000328:Adult; D015992:Body Mass Index; D002851:Chromatography, High Pressure Liquid; D003622:Dapsone / Q000097:blood* / Q000493:pharmacokinetics*; D006801:Humans; D007917:Leprostatic Agents / Q000097:blood* / Q000493:pharmacokinetics*; D056006:Leprosy, Multibacillary / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications
D007917:Leprostatic Agents; D003622:Dapsone